Kalaris Therapeutics Inc's fundamentals are relatively very healthy, with low ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 165 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.60.In the medium term, the stock price is expected to trend up.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Kalaris Therapeutics Inc is 5.56, ranking 349 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Key Metrics
The current valuation score of Kalaris Therapeutics Inc is 7.55, ranking 102 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.04, which is -75.57% below the recent high of -0.01 and -5970.17% above the recent low of -2.14.
The current earnings forecast score of Kalaris Therapeutics Inc is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 23.00 and a low of 5.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Kalaris Therapeutics Inc is 3.07, ranking 369 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.79 and the support level at 7.57, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Kalaris Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 71.45%, representing a quarter-over-quarter decrease of 10.03%. The largest institutional shareholder is The Vanguard, holding a total of 292.79K shares, representing 1.57% of shares outstanding, with 154.39% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kalaris Therapeutics Inc is 1.85, ranking 276 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Kalaris Therapeutics Inc’s latest ESG disclosure lags behind the Biotechnology & Medical Research industry average, suggesting potential exposures in governance structure, environmental management, or social responsibility that may amplify risk and warrant ongoing monitoring.
